Physician profile
Edward Ji
NPI 1184126575
$4,492.90
in general payments reported to CMS, 2019-2025
41 companies · $24.91 in 2025
The $24.91 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.85 · 2020: $16.50 · 2021: $1,751 · 2022: $1,702 · 2023: $979 · 2025: $24.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,004.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $370.26 | 2021-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.70 | 2021-2022 | |
| Csl Behring | $317.85 | 2021-2023 | Hizentra |
| Sk Life Science, INC. | $310.59 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $268.06 | 2021-2022 | |
| Eisai INC. | $248.43 | 2021-2023 | |
| Lilly USA, LLC | $230.99 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $225.87 | 2022 | |
| Novo Nordisk INC | $187.81 | 2022-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $170.28 | 2021-2023 | |
| Glaxosmithkline, LLC. | $164.22 | 2021-2023 | Arexvy |
| Pfizer INC. | $156.51 | 2021-2023 | |
| Amarin Pharma, INC. | $156.26 | 2021 | |
| Neurocrine Biosciences, INC. | $151.37 | 2022-2023 | Ongentys, Ingrezza |
| Harmony Biosciences LLC | $139.95 | 2021-2023 | Wakix |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Ji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.